Form 4: Amarin CEO Aaron Berg Reports Significant Equity Grants and Vesting

Amarin Corp PLC's President and CEO, Aaron Berg, reported the acquisition of 75,000 American Depositary Shares through RSU vesting, a tax-related disposition of 38,363 shares, and new grants of stock options and restricted stock units.

Summary

• Aaron Berg, President and CEO of Amarin Corp PLC, reported changes in his beneficial ownership of American Depositary Shares (ADS) on June 26, 2025.
• Berg acquired 75,000 ADS due to the vesting of previously granted Restricted Stock Units (RSUs).
• Concurrently, 38,363 ADS were disposed of at a price of $15.9 per share to cover tax liabilities associated with the vesting of securities, which was explicitly noted as not a market sale.
• Following these transactions, Berg's direct beneficial ownership of American Depositary Shares stands at 80,714.
• Additionally, on June 26, 2025, Berg was granted an option to purchase 37,500 ADS at an exercise price of $15.9, with vesting scheduled over eighteen months (50% on the first anniversary and the remainder eighteen months after the grant date).
• He also received a grant of 12,500 RSUs on June 26, 2025, which will vest in two equal installments on the first anniversary and eighteen months after the grant date.
• An earlier grant of 75,000 RSUs vested fully on June 26, 2025, leading to the reported acquisition of 75,000 ADS.
• Effective April 11, 2025, Amarin implemented an ADS ratio change where one ADS now represents twenty Ordinary Shares, and all reported figures reflect this adjustment.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation activities, including grants of new equity and vesting of existing awards, which generally indicates stability and ongoing incentive alignment. The disposition was for tax purposes, not a market sale, which is a neutral event. The future vesting schedules are positive for long-term alignment.

Positives

• Grant of 37,500 stock options, indicating future potential upside tied to company performance and aligning executive incentives.
• Grant of 12,500 Restricted Stock Units (RSUs), further aligning executive incentives with shareholder value over time.
• Vesting of 75,000 Restricted Stock Units (RSUs), resulting in the acquisition of 75,000 American Depositary Shares, demonstrating the realization of prior equity compensation.

Negatives

• Disposition of 38,363 American Depositary Shares at $15.9 to cover tax liabilities, which reduces direct beneficial ownership, though it is a non-market transaction.

Future Outlook

The document indicates future vesting schedules for newly granted stock options and restricted stock units, aligning executive incentives with long-term company performance. Specifically, the 37,500 stock options and 12,500 RSUs will vest over eighteen months, with initial vesting on the first anniversary of the grant date.

Industry Context

This filing reflects routine executive equity compensation activities within the pharmaceutical industry, where stock options and restricted stock units are common tools to incentivize and retain key management, aligning their interests with long-term shareholder value. The ADS ratio change is an internal corporate action that can affect share liquidity and perception but is not directly tied to broader industry trends.

Comparison to Industry Standards

• The use of stock options and restricted stock units for executive compensation is standard practice across the pharmaceutical and biotechnology industries, aligning executive incentives with long-term company performance and shareholder value.
• The vesting schedules, such as 50% on the first anniversary and the remainder at eighteen months, are typical for executive equity grants, designed to encourage retention and sustained performance.
• The disposition of shares for tax withholding upon vesting is a common and expected practice for equity compensation in the U.S. and globally, not indicative of a market sale.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the CEO's long-term interests with shareholder value. The tax-related disposition is a neutral event. The ADS ratio change impacts the number of ordinary shares represented by each ADS, which could affect per-share metrics but not the underlying value of holdings.
• Employees: The document pertains to executive compensation and does not directly impact general employees, though it sets a precedent for executive incentive structures.

Next Steps

• Future vesting of 37,500 stock options: 50% on the first anniversary of the grant date (June 26, 2025) and the remaining balance eighteen months after the grant date.
• Future vesting of 12,500 Restricted Stock Units: Two equal installments on the first anniversary of the grant date (June 26, 2025) and eighteen months after the grant date.

Key Dates

Recommendation

Keywords

Amarin Corp PLC, AMRN, Aaron Berg, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Beneficial Ownership, ADS Ratio Change, Executive Compensation